AR080884A1 - Conjugados de insulina-sirna - Google Patents

Conjugados de insulina-sirna

Info

Publication number
AR080884A1
AR080884A1 ARP110101227A ARP110101227A AR080884A1 AR 080884 A1 AR080884 A1 AR 080884A1 AR P110101227 A ARP110101227 A AR P110101227A AR P110101227 A ARP110101227 A AR P110101227A AR 080884 A1 AR080884 A1 AR 080884A1
Authority
AR
Argentina
Prior art keywords
refers
insulin
specifically
methods
metabolic diseases
Prior art date
Application number
ARP110101227A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR080884A1 publication Critical patent/AR080884A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere de forma general a compuestos terapéuticos y métodos utiles para tratar a enfermedades en seres humanos. Más concretamente, se refiere a métodos y reactivos utiles para tratar a seres humanos que padecen enfermedades metabolicas. Más concretamente, se refiere a conjugados covalentes de insulina y análogos con derivados de ácidos nucleicos que son capaces de modular la expresion de genes. Además, esta se refiere al uso de dichas insulinas conjugadas para el tratamiento de enfermedades metabolicas, incluyendo la diabetes mellitus. Reivindicacion 1: El compuesto quimérico que comprende una insulina y su siRNA.
ARP110101227A 2010-04-14 2011-04-12 Conjugados de insulina-sirna AR080884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305388 2010-04-14

Publications (1)

Publication Number Publication Date
AR080884A1 true AR080884A1 (es) 2012-05-16

Family

ID=42633135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101227A AR080884A1 (es) 2010-04-14 2011-04-12 Conjugados de insulina-sirna

Country Status (4)

Country Link
AR (1) AR080884A1 (es)
TW (1) TW201141513A (es)
UY (1) UY33326A (es)
WO (1) WO2011128374A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI608847B (zh) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3500581A4 (en) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JP2606915B2 (ja) 1987-02-25 1997-05-07 ノボ ノルディスク アクティーゼルスカブ 新規インシュリン誘導体
UA45321C2 (uk) 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US20060019913A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
AU2003283951A1 (en) 2002-05-23 2004-03-03 Ceptyr, Inc. Modulation of biological signal transduction by rna interference
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
WO2005002515A2 (en) * 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
PL1907419T3 (pl) 2005-07-08 2011-08-31 Biocon Ltd Wytwarzanie koniugatów insuliny
WO2007043059A1 (en) 2005-10-13 2007-04-19 Biocon Limited Process for the preparation of insulin conjugates.
KR20080066987A (ko) 2005-11-04 2008-07-17 나스텍 파마수티컬 컴퍼니 인코포레이티드 ｓｉＲＮＡ에 대한 전달 운반체로서의 펩티드-다이서 기질ＲＮＡ 접합체들
CA2678646A1 (en) 2007-03-05 2008-09-12 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery

Also Published As

Publication number Publication date
TW201141513A (en) 2011-12-01
WO2011128374A1 (en) 2011-10-20
UY33326A (es) 2011-12-01

Similar Documents

Publication Publication Date Title
AR080884A1 (es) Conjugados de insulina-sirna
CY1120685T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
UY31596A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
NZ595189A (en) Combination therapy with thiocolchicine derivatives
CL2013000020A1 (es) Metodo para controlar una plaga de insectos coleopteros que comprende suministrar a una plaga de coleopteros o su entorno una composicion que contiene al menos una proteina activa contra colepteros, tal como la proteina cry3a modificada activa contra lepidopteros, tal como la proteina cry1ab
WO2010036918A3 (en) Intracellular dna receptor
AR083715A1 (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
NZ595891A (en) Modulation of inflammatory responses by factor xi
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
CL2011003094A1 (es) Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv.
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas

Legal Events

Date Code Title Description
FB Suspension of granting procedure